Brief: Spruce Biosciences And Kaken Pharmaceutical Announce Strategic Partnership And Exclusive Licensing Agreement To Develop And Commercialize Tildacerfont For Cah In Japan
05/01/2023 22:05
Jan 5 (Reuters) - Kaken Pharmaceutical Co Ltd 4521.T :
* SPRUCE BIOSCIENCES AND KAKEN PHARMACEUTICAL ANNOUNCE
STRATEGIC
PARTNERSHIP AND EXCLUSIVE LICENSING AGREEMENT TO DEVELOP AND
COMMERCIALIZE TILDACERFONT FOR CAH IN JAPAN
* SPRUCE BIOSCIENCES INC - DEAL ADVANCES STRATEGY TO PARTNER
TILDACERFONT COMMERCIAL RIGHTS OUTSIDE UNITED STATES
* SPRUCE BIOSCIENCES - KAKEN WILL ALSO BE RESPONSIBLE FOR
SECURING
AND MAINTAINING REGULATORY APPROVALS NECESSARY TO MARKET AND
SELL TILDACERFONT IN JAPAN
* SPRUCE BIOSCIENCES-TO GET $15 MILLION UPFRONT PAYMENT PLUS
DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS, TIERED DOUBLE-DIGIT
ROYALTIES ON NET SALES IN JAPAN
Source text for Eikon: ID:nBwbMWB7Ba
Further company coverage: 4521.T
((Reuters.Briefs@thomsonreuters.com;;))